Increase in CD30 ligand/CD153 and TNF-α expressing mast cells in basal cell carcinoma

Cancer Immunology, Immunotherapy

Volumn 56, Issue 9, 2007, Pages 1407-1415

  Diaconu, Nicolae Costin ^a   Kaminska, Renata ^b   Naukkarinen, Anita ^a   Harvima, Rauno J ^a   Nilsson, Gunnar ^c   Harvima, Ilkka T ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b Ctrl Ostrobothnian Central Hospital   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytokine; Ligand; Receptor; Skin cancer; TNF family

Indexed keywords

CD30 ANTIGEN; CD30 LIGAND; CD40 ANTIGEN; CD40 LIGAND; STEM CELL FACTOR RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CELL ACTIVATION; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MAST CELL; PRIORITY JOURNAL; SKIN CARCINOGENESIS;

AGED; AGED, 80 AND OVER; ANTIGENS, CD30; CARCINOMA, BASAL CELL; CD30 LIGAND; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; MAST CELLS; MIDDLE AGED; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34347405512     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0290-7     Document Type: Article

References (35)

1. Ackermann L, Harvima IT (1998) Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch Dermatol Res 290:353-359
2. Ackermann L, Harvima IT, Pelkonen J, Ritamäki-Salo V, Naukkarinen A, Harvima RJ, Horsmanheimo M (1999) Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br J Dermatol 140:624-633
3. Aoki M, Pawankar R, Niimi Y, Kawana S (2003) Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES. Int Arch Allergy Immunol 130:216-223
4. Bengtsson Å (2001) The role of CD30 in atopic disease. Allergy 56:593-603
5. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST (2006) Mast cells and cutaneous malignancies. Mod Pathol 19:149-159
6. Dimitriadou V, Koutsilieris M (1997) Mast cell-tumor cell interactions: for or against tumor growth and metastasis? Anticancer Res 17:1541-1550
7. Fischer M, Harvima IT, Carvalho RFS, Möller C, Naukkarinen A, Enblad G, Nilsson G (2006) Mast cell CD30 ligand is up-regulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 116:2748-2756
8. Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6:135-142
9. Gibbs BF, Wierecky J, Welker P, Henz BM, Wolff HH, Grabbe J (2001) Human skin mast cells rapidly release preformed and newly generated TNF-α and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol 10:312-320
10. Grimbaldeston MA, Skov L, Baadsgaard O, Skov BG, Marshman G, Finlay-Jones JJ, Hart PH (2000) High dermal mast cell prevalence is a predisposing factor for basal cell carcinoma in humans. J Invest Dermatol 115:317-320
11. Grimbaldeston MA, Skov L, Finlay-Jones JJ, Hart PH (2002) Increased dermal mast cell prevalence and susceptibility to development of basal cell carcinoma in humans. Methods 28:90-96
12. Henz BM, Maurer M, Lippert U, Worm M, Babina M (2001) Mast cells as initiators of immunity and host defense. Exp Dermatol 10:1-10
13. Hjertson M, Kivinen PK, Dimberg L, Nilsson K, Harvima IT, Nilsson G (2003) Retinoic acid inhibits in vitro-development of mast cells but has no marked effect on mature human skin tryptase- and chymase-positive mast cells. J Invest Dermatol 120:239-245
14. Horsmanheimo L, Harvima IT, Järvikallio A, Harvima RJ, Naukkarinen A, Horsmanheimo M (1994) Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol 131:348-353
15. Humphreys TR, Monteiro MR, Murphy GF (2000) Mast cells and dendritic cells in basal carcinoma stroma. Dermatol Surg 26:200-203
16. Huttunen M, Naukkarinen A, Horsmanheimo M, Harvima IT (2002) Transient production of stem cell factor in dermal cells but increasing expression of Kit receptor in mast cells during normal wound healing. Arch Dermatol Res 294:324-330
17. Janowski P, Strzelecki M, Brzezinska-Blaszczyk E, Zalewska A (2001) Computer analysis of normal and basal cell carcinoma mast cells. Med Sci Monit 7:260-265
18. Kashiwakura J, Yokoi H, Saito H, Okayama Y (2004) T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol 173:5247-5257
19. Kooy AJW, Prens EP, van Heukelum A, Vuzevski VD, van Joost T, Tank B (1999) Interferon-γ-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10? J Pathol 187:351-357
20. Kristensen M, Chu CQ, Eedy DJ, Feldmann M, Brennan FM, Breathnach SM (1993) Localization of tumour necrosis factor-alpha (TNF-α) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 94:354-362
21. Malejczyk M, Jozwiak J, Jablonska S, Pfister H, Majewski S, Malejczyk J (2005) Circulating soluble tumour necrosis factor receptors in patients with epidermodysplasia verruciformis as compared to patients with cutaneous tumours in the general population. Oncol Rep 13:151-155
22. Marshall JS, Jawdat DM (2004) Mast cells in innate immunity. J Allergy Clin Immunol 114:21-27
23. Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson K, Sundström C, Enblad G, Nilsson G (2001) Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 114:616-623
24. Ohta Y, Hamada Y (2004) In situ expression of CD40 and CD40 ligand in psoriasis. Dermatology 209:21-28
25. Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR (2002) CD40 activation as potential tool in malignant neoplasms. Tumori 88:361-366
26. Pasch MC, Timár KK, van Meurs M, Heydendael VMR, Bos JD, Laman JD, Asghar SS (2004) In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J Pathol 203:839-848
27. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C (1997) Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the FcεRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 99:1465-1466
28. Poniecka AW, Alexis JB (1999) An immunohistochemical study of basal cell carcinoma and trichoepithelioma. Am J Dermatopathol 21:332-336
29. Rossi FM, Degan M, Mazzocut-Zecchin L, Di Francia R, Aldinucci D, Pinto A, Gattei V (2001) CD30L up-regulates CD30 and IL-4 expression by T cells. FEBS Lett 508:418-422
30. Skov L, Allen MH, Bang B, Francis D, Barker JN, Baadsgaard O (2003) Basal cell carcinoma is associated with high TNF-alpha release but nor with TNF-alpha polymorphism at position-308. Exp Dermatol 12:772-776
31. Tamada K, Chen L (2006) Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 55:355-362
32. Viac J, Schmitt D, Claudy A (1997) CD40 expression in epidermal tumors. Anticancer Res 17:569-572
33. Weber A, Maurer M (2005) Skin site mast cell numbers correlate with rates of nodular growth, but not incidence, of basal cell carcinoma. Dermatology 211:298-299
34. Wiley SR, Goodwin RG, Smith CA (1996) Reverse signaling via CD30 ligand. J Immunol 157:3635-3639
35. Yamamoto T, Katayama I, Nishioka K (1997) Expression of stem cell factor in basal cell carcinoma. Br J Dermatol 137:709-713